The earnings call summary presents a mixed outlook. While there is optimism about aficamten's potential approval and commercial launch readiness, the timeline extends into 2025-2026, delaying immediate impact. The Q&A reveals uncertainties about trial data, pricing, and REMS finalization, which could dampen short-term enthusiasm. The lack of immediate catalysts and the market's focus on future developments suggest a neutral stock price movement in the short term.